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Reaction of (()-eseroline (1) with alkyl, aryl and aralkylisocyanates afforded a series of carbamate analogues of ( )-phy- 
sostigmine (2) which were assayed for inhibition of acetyl- and butyrylcholinesterase (AChE and BChE. respectively) 
in vitro. Included in this study were two N-alkyl-substituted carbamates 9 and 14 obtained from (-)-eseroline (1) with 
dialkylcarbamoyl chlorides, and allophanates 12 and 13 obtained as by-products in the reaction of I and benzylcarbamoyl 
eseroline (8) with benzyl isocyanate. Whereas none of the analogues studied was more potent than 2 against electric eel 
AChE. and carbamates 6, 7 and 8 were all more than 3 times more potent against human plasma BChE than 2. 
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1. INTRODUCTION 
(- )-Physostigmine (2), also named (-)-eserine, 
is a carbamate ester alkaloid from Calabar beans 
[l]. It is a potent inhibitor of acetylcholinesterase 
(AChE) as well as butyrylcholinesterase (BChE) 
and has been used clinically in the treatment of 
glaucoma, atropine intoxication, myasthenia 
gravis [2] and more recently, in experimental trials 
in Alzheimer’s disease [3]. Although first isolated 
in 1864 by Jobst and Hesse [4], relatively little at- 
tention has been given to the relationship between 
structure and activity of (- )-physostigmine with 
the aim of obtaining compounds that might be 
non-clinically more useful (i.e. longer biological 
half-life, better specificity for AChE rather than 
BChE) than ( - )-physostigmine. 
With the discovery of a practical synthesis of 
(-)-eseroline (1) [5] and an easy route to 1 from 
commercially available ( - )-physostigmine (2) [6] 
the preparation of carbamate analogues of 2 
became feasible. In the present report, a number of 
analogues of ( - )-physostigmine were prepared 
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and their potencies (I&) were evaluated in vitro 
against electric eel AChE and human plasma 
BChE. 
2. MATERIALS AND METHODS 
The starting material, (-)-eseroline (l), was prepared from 
(- )-physostigmine (2, Fluka or Aldrich) by the published pro- 
cedure [6] and stored as fumarate salt. The preparation of the 
two carbamates 6 and 8 given below is representative of the 
preparation of the carbamates listed in table I. Preparation of 
benzyl carbamate 8 afforded at the same time the less polar 
allophanate 12 as a by-product. Reaction of 1 with diethylcar- 
bamoyl chloride afforded 14 by the procedure elaborated for its 
N-methyl analogue 9 [6]. Most carbamates and allophanates 
were obtained as oils with the exception of 3, 4, 5 and 9 which 
were crystalline. Compounds 3 and 4 were characterized, as 
fumarate salts. The purity of the compounds was assessed by 
TLC (silica gel, CHClj/MeOH = 10: I). Optical rotations were 
measured in chloroform solution and the molecular composi- 
tion confirmed by mass spectra (CI-MS) and elemental analysis. 
2.1. (-)-Octylcarbamoyleseroline (6J 
(-)-Eseroline (1, 150 mg, 0.68 mmol) was dissolved in 
anhydrous ether (15 ml) and a small piece of sodium (-5 mg) 
added. After stirring for 2 min in a nitrogen atmosphere, oc- 
tylisocyanate (130 mg, 0.83 mmol) was added and the remain- 
ing sodium removed. The solvent was evaporated under 
vacuum and the residue flash-chromatographed on a silica gel 
column (15 g) with 500 ml CHzClz/MeOH (100 : 1) followed by 
500 ml CH2CVMeOH (100:4) to afford, after evaporation of 
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the solvent, the carbamate 6 as an oil (180 mg, 70.9%): [cr]o 
-58.4” (c = 0.6, CHCls); MS (Cl) m/z 374 (M+ + 1). Anal. 
Calc. for Cz2HjsNsO~: C, 70.78; H, 9.45; N, 11.26. Found: C, 
70.54; H, 9.48; N, 11.18. 
2.2. (-)-Benzylcarbamoyleseroline (8) and dibenzylallo- 
phanate (13) 
(-)-Eseroline (1, 300 mg, 1.37 mmol) was dissolved in 
anhydrous ether (15 ml) and a small piece of sodium (-5 mg) 
added. After stirring for 2 min in a nitrogen atmosphere, ben- 
zylisocyanate (272 mg, 2.02 mmol) was added and the remain- 
ing sodium removed with a pincer. The reaction mixture was 
stirred at room temperature for 20 mitt in a nitrogen at- 
mosphere, the solvent removed in vacuum and the residue flash- 
chromatographed on a silica gel column (15 g) with 500 ml 
CHzCWMeOH = 100: 1 followed by 500 ml CHKWMeOH = 
100:2 affording two products. The less polar material 13 was 
obtained as a gum (291 mg, 43.8%): [CY]D -51.6” (c = 1.5, 
CHCls); MS(C1) m/z 485 (M++ 1). Anal. Calc. for 
C2sHsZN40s: C, 71.81; H, 6.66; N, 11.56. Found: C, 71.93; H, 
6.69; N, 11.56. The more polar fraction, also obtained as a 
gum, was the benzylcarbamate 8 (239 mg, 49.6%): [a]o - 66.4” 
(c = 0.7, CHCls); MS(C1) m/z 352 (M+ + 1). Anal. Calc. for 
C2,HZ5N,02: C, 71.76; H, 7.17; N, 11.96. Found: C, 71.62; H, 
7.22; N, 11.90. 
Similar procedures were employed to synthesize the other 
compounds shown in table 1. 
2.3. Experimental 
AChE and BChE activities were assayed (final incubation 
volume = 1 .O ml) in 50 pl aliquots of electric eel AChE (type 
III, 1000 units/mg protein, diluted 1 :40000; Sigma, St. Louis, 
MO) and 50 pl human plasma (diluted I : 200), respectively, us- 
ing the spectrophotometric method of Ellman [7]. 0.5 mM 
acetylmethylthiocholine and 0.5 mM butyrylthiocholine were 
used as specific substrates for AChE and BChE, respectively. 
The production of the yellow 5-thio-2-nitrobenzoate anion 
(produced by the reaction of 5 : 5-dithiobis-2-nitrobenzoic acid 
with thiocholine released by the enzymatic hydrolysis of either 
acetylmethylthiocholine or butyrylthiocholine) was followed at 
a wavelength of 412 nm. 
AChE and BChE activities were determined in the presence 
of varying concentrations of each compound (10-‘“-10-4 M) 
and were expressed as a percentage of the activity observed in 
the absence of test compound (table 1). 
3. RESULTS AND DISCUSSION 
3.1. Acetylcholinesterase inhibition 
None of the (-)-physostigmine derivatives 
studied was as potent against electric eel AChE as 
(- )-physostigmine itself (1C50 = 61 f 18 nM). Ex- 
tension of the carbamoyl side chain by the addition 
of either an octyl or butyl group resulted in com- 
Table 1 
ICso of (-)-physostigmine and carbamate analogues versus electric eel AChE and human plasma BChE 
Compounds 
No. Name 
Electric eel AChE 
ICSO Relative 
(nM) potency (070) 
Plasma BChE ICso BChE/ 
I&, AChE 
lCS0 Relative 
(nM) potency (%) 
2 
6 
7 
3 
8 
9 
4 
5 
12 
10 
11 
13 
15 
16 
14 
1 
( - )-physostigmine 
octylcarbamoyl eseroline 
butylcarbamoyl eseroline 
N-phenylcarbamoyl eseroline 
benzylcarbamoyl eseroline 
N-methyl physostigmine 
methoxyphenylcarbamoyl eseroline 
chlorophenylcarbamoyl eseroline 
N-benzyl-N-methylallophanyl eseroline 
(R)( +)-o-methylbenzylcarbamoyl 
eseroline 
(s)( - )-a-methylbenzylcarbamoyl 
eseroline 
N-benzyl-N-benzylallophanyl eseroline 
t-butylcarbamoyl eseroline 
N-isopropylcarbamoyl eseroline 
N-diethylcarbamoyl eseroline 
eseroline 
61 f 18 100 14 k 6 100 0.23 
110 * 11 55 3.6 k 1.0 389 0.03 
152+ 9 40 4.1 + 1.3 341 0.03 
350 * 90 17 1300 f 400 1 3.71 
460 I?- 80 13 2.7 f 1.6 520 0.01 
970 + 260 6 420 f 120 3 0.43 
1680 + 380 4 28 + 2 50 0.02 
1800 + 125 3 4000 + 1290 <I 2.22 
6300 1 500 + 150 3 0.08 
<l 160 + 90 9 0.02 
11000 <l 1600 <l 0.15 
> 10000 <l 1600 <1 <0.16 
> 10000 <l 2000 <l <0.2 
35000 <1 > 100000 <l >28.6 
40000 <1 40 000 <I 1.0 
> 10000 <1 10000 <1 < 1.0 
Values shown are mean f standard deviation of 3-5 different assays. The ratio of 1% BChE : I& AChE is an index of the relative 
selectivity of a compound for AChE or BChE: values > 1 mean the compound is more potent against AChE than BChE whereas values 
< 1 indicate that the compound is more potent against BChE than AChE 
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pounds, octylcarbamoyl eseroline (6) and butylcar- 
bamoyl eseroline (7), approximately half as potent 
as ( - )-physostigmine (IGO and relative potencies, 
110 f 11 nM, 55% and 152 + 9 nM, 4070, respec- 
tively), suggesting that lengthening of the car- 
bamoyl side chain does not greatly reduce the 
ability of the carbonyl group to interact with the 
esteratic site of electric eel AChE. However, the 
addition of either a N-phenyl or benzyl group 
reduces the potency of the resulting compounds 
(N-phenylcarbamoyl eseroline (3) and benzylcar- 
bamoyl eseroline (8)) much more (IGO and relative 
potencies, 350 ? 90 nM, 17% and 460 +- 80 nM, 
13%) respectively) indicating that the bulk of these 
groups reduces the interaction between the car- 
bony1 group and the esteratic site. Indeed, when 
the bulk of the phenyl group is further increased by 
the addition of either a chlorine atom or a methoxy 
group, the potency of the resulting compounds 
(chlorophenylcarbamoyl eseroline (5) and methox- 
yphenylcarbamoyl eseroline (4), respectively) is 
reduced approx. 5-fold compared to phenylcar- 
bamoyl eseroline (3) and to less than 5% of (- )- 
physostigmine. Compounds with very bulky car- 
bamoyl side chain additions, such as N-benzyl-N- 
methylallophanyl eseroline (12) and N-dibenzyl- 
allophanyl eseroline (13), showed low anti-AChE 
potencies (relative potency < 1070). 
Methylation of the carbamoyl nitrogen resulted 
in a compound (N-methylphysostigmine (9)) which 
was less potent (IGo = 970 + 260 nM, relative 
potency: 6%) than (-)-physostigmine (2). This 
result differs from an earlier report in which N- 
methylphysostigmine (9) was reported to be ap- 
prox. 20-times more potent than (-)- 
physostigmine against electric eel AChE [8]. 
Since (-)-physostigmine is an inhibitor by vir- 
tue of its carbamoyl group, it is not surprising that 
Compound 
no. 
R MW [LY]D (in CHKl,) Properties 
1 
2 
3 
4 
11 
12 
13 
14 
15 
16 
H 218.29 - 109.7” (c= 1, MeOH) 
CONHCHx 215.34 -76” (c= 1.3) 
CONHPh 337.41 -78.5” (c=2, EtOH) 
CONHPh-OMe(p) 367.44 - 73.2” (c=O.5) 
CONHPh-Cl(P) 
CONH(CH&CH3 
CONH(CHz),CHj 
CONHBn 
CON(CH& 
CH3 
r 
(S)PhCkNHCO 
CH3 
v 
(R)PhCHNHCO 
CONCH3CONHBn 
CONBnCONHBn 
CON(CHzCH& 
CONHC(CH& 
CONHCH(CH3)z 
371.86 
373.31 
317.42 
351.44 
289.37 
365.47 - 104” (c= 0.7) 
365.47 + 3.3” (c= 1) 
408.50 - 186.9” (c= 1) 
484.59 -51.6” (c=1.5) 
317.43 - 63.6” (c= 1) 
317.43 -55.8” (c= 1.2) 
303.40 -65.5” (c=2) 
71.8” (c=O.l) 
58.4’ (c=O.6) 
74.3O (c=O.3) 
66.4” (c= 0.7) 
- 74.2” (c= 1) 
m.p. 125-126T 
m.p. 105-106Tb 
m.p. 148-149Tc 
Fumarate: m.p. 167-168°C 
[IT+, -97.8” (c=O.l, MeOH) 
m.p. 129-130°C 
Fumarate: m.p. 180-183°C 
[a]n -67.5” (c= 1, MeOH) 
m.p. 186-188°C 
oil 
oil 
gum 
m.p. 73.5-74.O”C 
gum 
gum 
gum 
oil 
gum 
gum 
a Ref. [6] 
b Merck Index, p.7267, 10th edition 
’ Beilstein, 1954, p.333, El123 
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when this bond is hydrolyzed the resulting com- 
pound, eseroline, has, as reported previously, very 
little anti-AChE action (IGo > 10000 nM) [8]. 
3.2. Butyrylcholinesterase inhibition 
Unlike electric eel AChE, several of the (-)- 
physostigmine derivatives were more potent 
against human plasma BChE than (-)- 
physostigmine itself. Thus, the octyl-, butyl- and 
benzyl-carbamoyl eseroline derivatives (6, 7 and 8) 
were more potent against plasma BChE (IGO and 
relative potencies 3.6 f 1 .O nm, 389%; 4.1 f 
1.3 nM, 341% and 2.7 f 1.6 nM, 520%, respec- 
tively) than (-)-physostigmine (I& = 14 -t 
6 nM). Interestingly, whereas the benzyl- and N- 
phenylcarbamoyl derivatives (8 and 3, respectively) 
were approximately equipotent against AChE, 
benzylcarbamoyl eseroline (8) was approximately 
500 times more potent against plasma BChE 
(I&, = 2.7 ? 1.6 nM, relative potency 520%) than 
N-phenylcarbamoyl eseroline (3) (ICW = 1300 f 
400 nM, relative potency 1%). However, the addi- 
tion of a methoxy group to the phenyl group in N- 
phenylcarbamoyl eseroline increased the potency 
approximately 50-fold (1% methoxyphenylcar- 
bamoyl eseroline (4) = 28 + 2 nM, relative potency 
50%), but caused a 5-fold decrease in potency 
against electric eel AChE. Addition of a chlorine 
atom to the phenyl group reduces the potency of 
phenylcarbamoyl eseroline still further (IGo 
chlorophenylcarbamoyl eseroline (5) = 4000 f 
1290 nM, relative potency < 1%). 
As with AChE, the addition of increasingly 
bulky side groups resulted in a decrease in the 
potency of the compounds against plasma BChE, 
and eseroline itself was a poor inhibitor (1% > 
10000 nM, relative potency < 1%). 
4. DISCUSSION 
Although ( - )-physostigmine and the majority 
of the (-)-physostigmine derivatives were more 
potent against human plasma BChE than electric 
eel AChE, suggesting that these compounds might 
be more selective for BChE than AChE, it should 
be emphasized that there are interspecies variations 
in the inhibitory properties of AChE and BChE 
[9]. Consequently, it is uncertain whether the dif- 
ferences in potencies towards AChE and BChE 
observed in the present report are due to the com- 
pounds themselves or are merely a consequence of 
interspecies variability (i.e. is this same pattern of 
inhibitory properties seen in AChE and BChE 
derived from the same species?). 
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